 |
2020 News Releases
December 11, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
December 11, 2020 - Puma Biotechnology Presents Efficacy and Safety Outcomes from the
Phase III NALA Trial at the 2020 SABCS
Read
December 9, 2020 - Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Read
December 9, 2020 - Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
Read
December 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted
Read
November 17, 2020 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Read
November 6, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
November 5, 2020 - Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer
Read
November 5, 2020 - Puma Biotechnology Reports Third Quarter 2020 Financial Results
Read
November 3, 2020 - Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
Read
October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers
Read
October 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer
Read
October 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
September 8, 2020 - Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Read
September 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
August 19, 2020 - Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Read
August 10, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
August 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results
Read
July 27, 2020 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
Read
July 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 16, 2020 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read
July 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
June 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
May 8, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
May 7, 2020 - Puma Biotechnology Reports First Quarter 2020 Financial Results
Read
May 7, 2020 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read
May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
Read
April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Read
April 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read
April 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
March 25, 2020 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
March 5, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
February 28, 2020 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read
February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read
February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
February 7, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
February 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Read
January 13, 2020 - Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Read
January 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read
January 7, 2020 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read
|
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
|
